Difference between revisions of "Apalutamide (Erleada)"
Jump to navigation
Jump to search
m |
m |
||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
Competitive androgen receptor (AR) inhibitor | Competitive androgen receptor (AR) inhibitor | ||
| − | = | + | ==Diseases for which it is used== |
| − | ==[[Prostate cancer]] | + | *[[Prostate cancer]] |
# Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. Epub 2017 Feb 17. [https://www.ncbi.nlm.nih.gov/pubmed/28213364 PubMed] | # Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. Epub 2017 Feb 17. [https://www.ncbi.nlm.nih.gov/pubmed/28213364 PubMed] | ||
| − | # Rexer H, Graefen M. | + | # Rexer H, Graefen M. Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO. Urologe A. 2017 Feb;56(2):243-244. German. [https://www.ncbi.nlm.nih.gov/pubmed/28144693 PubMed] |
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *2/14/2018: FDA approved "for patients with [[prostate cancer|non-metastatic castration-resistant prostate cancer (NM-CRPC)]]." | ||
| + | ==Also known as== | ||
| + | *'''Code name:''' ARN-509 | ||
| + | *'''Brand name:''' Erleada | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| Line 13: | Line 19: | ||
[[Category:Antiandrogens]] | [[Category:Antiandrogens]] | ||
| − | [[Category: | + | [[Category:Prostate cancer medications]] |
| + | |||
| + | [[Category:Drugs FDA approved in 2018]] | ||
Revision as of 01:49, 19 February 2018
Mechanism of action
Competitive androgen receptor (AR) inhibitor
Diseases for which it is used
- Rathkopf DE, Antonarakis ES, Shore ND, Tutrone RF, Alumkal JJ, Ryan CJ, Saleh M, Hauke RJ, Bandekar R, Maneval EC, de Boer CJ, Yu MK, Scher HI. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer Res. 2017 Jul 15;23(14):3544-3551. Epub 2017 Feb 17. PubMed
- Rexer H, Graefen M. Phase III study for local or locally advanced prostate cancer : Randomized, double-blind, placebo-controlled phase 3 study of apalutamide in patients with local high-risk prostate cancer or locally advanced prostate cancer receiving primary radiotherapy (ATLAS) - study AP 90/15 of the AUO. Urologe A. 2017 Feb;56(2):243-244. German. PubMed
History of changes in FDA indication
- 2/14/2018: FDA approved "for patients with non-metastatic castration-resistant prostate cancer (NM-CRPC)."
Also known as
- Code name: ARN-509
- Brand name: Erleada